Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: EST001
MIFTS: 52

Estrogen-Receptor Positive Breast Cancer

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Estrogen-Receptor Positive Breast Cancer

About this section

MalaCards integrated aliases for Estrogen-Receptor Positive Breast Cancer:

Name: Estrogen-Receptor Positive Breast Cancer 12 15 17

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0060075
Sources

Summaries for Estrogen-Receptor Positive Breast Cancer

About this section
Disease Ontology : 12 A breast cancer that is characterized by the presence of estrogen receptors.

MalaCards based summary : Estrogen-Receptor Positive Breast Cancer is related to fallopian tube carcinoma and estrogen-receptor negative breast cancer. An important gene associated with Estrogen-Receptor Positive Breast Cancer is HSPB8 (Heat Shock Protein Family B (Small) Member 8), and among its related pathways/superpathways are Signaling by GPCR and Akt Signaling. The drugs Fulvestrant and Exemestane have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lung, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Estrogen-Receptor Positive Breast Cancer

About this section

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)
# Related Disease Score Top Affiliating Genes
1 fallopian tube carcinoma 30.4 ERBB2 ESR1 PGR TP53
2 estrogen-receptor negative breast cancer 30.3 AR ERBB2 ESR1 FOXA1 PGR
3 breast cancer 29.5 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
4 vestibular gland benign neoplasm 10.4 ESR1 PGR
5 bartholin's gland adenoma 10.4 ESR1 PGR
6 scirrhous adenocarcinoma 10.4 ERBB2 PGR
7 breast apocrine carcinoma 10.4 ERBB2 PGR
8 vulvar syringoma 10.4 ESR1 PGR
9 lung leiomyoma 10.4 ESR1 PGR
10 endometrium carcinoma in situ 10.4 PGR TP53
11 breast papillomatosis 10.4 CCND1 ERBB2
12 vulvar benign neoplasm 10.4 ESR1 PGR
13 trigonitis 10.4 ESR1 PGR
14 vulvar leiomyoma 10.4 ESR1 PGR
15 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
16 intracystic papillary adenoma 10.4 ERBB2 PGR
17 glassy cell carcinoma of the cervix 10.4 ERBB2 ESR1 PGR
18 bartholin's duct cyst 10.4 AR TP53
19 breast metaplastic carcinoma 10.4 ERBB2 PGR
20 predominantly cortical thymoma 10.4 ESR1 PGR
21 breast medullary carcinoma 10.4 ERBB2 ESR1 PGR
22 breast scirrhous carcinoma 10.4 ERBB2 ESR1 PGR
23 comedo carcinoma 10.4 ERBB2 ESR1
24 adult hepatocellular carcinoma 10.4 PIK3CA TP53
25 non-proliferative fibrocystic change of the breast 10.3 CCND1 ERBB2 TP53
26 female reproductive endometrioid cancer 10.3 ESR1 PGR TP53
27 cervical carcinosarcoma 10.3 ESR1 PGR TP53
28 inflammatory breast carcinoma 10.3 ERBB2 ESR1 PGR
29 glycogen-rich clear cell breast carcinoma 10.3 ESR1 PGR TP53
30 lipid-rich carcinoma 10.3 ERBB2 ESR1 PGR
31 adenosarcoma 10.3 ESR1 PGR TP53
32 mammary paget's disease 10.3 ERBB2 ESR1 PGR
33 oncocytic breast carcinoma 10.3 AR ESR1 PGR
34 progesterone-receptor negative breast cancer 10.3 ERBB2 PGR
35 tubular adenocarcinoma 10.3 ERBB2 ESR1 PGR
36 microglandular adenosis 10.3 ERBB2 PGR TP53
37 peritoneal benign neoplasm 10.3 AR ESR1 PGR
38 diffuse peritoneal leiomyomatosis 10.3 AR ESR1 PGR
39 bartholin's gland benign neoplasm 10.3 ESR1 PGR
40 uterine corpus serous adenocarcinoma 10.3 ERBB2 PIK3CA TP53
41 malignant spiradenoma 10.3 PIK3CA TP53
42 breast squamous cell carcinoma 10.3 ERBB2 PIK3CA TP53
43 mixed cell type cancer 10.3 ERBB2 PGR TP53
44 primary peritoneal carcinoma 10.3 ERBB2 PGR TP53
45 papillary adenocarcinoma 10.3 ERBB2 PGR TP53
46 esophageal disease 10.3 CCND1 ERBB2 TP53
47 adrenocortical carcinoma, hereditary 10.3 CYP19A1 PIK3CA TP53
48 postmenopausal atrophic vaginitis 10.3 AR ESR1
49 leiomyoma 10.3 CYP19A1 ESR1 PGR
50 myoma 10.3 CYP19A1 ESR1 PGR

Graphical network of the top 20 diseases related to Estrogen-Receptor Positive Breast Cancer:



Diseases related to Estrogen-Receptor Positive Breast Cancer
Sources

Symptoms & Phenotypes for Estrogen-Receptor Positive Breast Cancer

About this section

GenomeRNAi Phenotypes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

27 (show top 50) (show all 54)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.38 MTOR PIK3CA
2 Decreased viability GR00107-A-1 10.38 HSPB8
3 Decreased viability GR00221-A-1 10.38 AKT1 ESR1 HSPB8 MTOR PIK3CA
4 Decreased viability GR00221-A-2 10.38 AKT1 ESR1 PIK3CA
5 Decreased viability GR00221-A-3 10.38 AKT1 ERBB2
6 Decreased viability GR00221-A-4 10.38 AKT1 ESR1 HSPB8 MTOR PIK3CA ERBB2
7 Decreased viability GR00301-A 10.38 HSPB8
8 Decreased viability GR00342-S-1 10.38 MTOR
9 Decreased viability GR00342-S-2 10.38 MTOR
10 Decreased viability GR00402-S-2 10.38 AKT1 ESR1 HSPB8 MTOR PIK3CA ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.24 MTOR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.24 MTOR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.24 FOXA1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.24 FOXA1 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.24 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.24 FOXA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.24 NCOA3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.24 FOXA1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.24 NCOA3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.24 CCND1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.24 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.24 AKT1 CCND1 FOXA1 PIK3CA MTOR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.24 CCND1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.24 PIK3CA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.24 AKT1 CCND1 FOXA1 NCOA3 PIK3CA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.24 FOXA1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.24 PIK3CA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.24 CCND1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.24 FOXA1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.24 CCND1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.24 CCND1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.24 FOXA1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.24 CCND1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.24 CCND1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.24 AKT1 FOXA1 PIK3CA MTOR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.24 PIK3CA
37 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.24 AKT1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.24 FOXA1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.24 AKT1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.24 MTOR
41 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.24 AKT1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.24 NCOA3
43 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.24 AKT1 MTOR
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 10.11 FOXA1
45 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.11 CCND1
46 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.11 MTOR
47 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.11 CCND1
48 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 10.11 CCND1
49 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.11 CCND1 FOXA1 PIK3CA
50 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.11 RAB31

MGI Mouse Phenotypes related to Estrogen-Receptor Positive Breast Cancer:

47 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.46 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
2 homeostasis/metabolism MP:0005376 10.43 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
3 behavior/neurological MP:0005386 10.41 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
4 endocrine/exocrine gland MP:0005379 10.4 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
5 cardiovascular system MP:0005385 10.37 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
6 growth/size/body region MP:0005378 10.36 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
7 immune system MP:0005387 10.36 AKT1 AR CCND1 CYP19A1 ESR1 FGFR2
8 mortality/aging MP:0010768 10.33 AKT1 AR CCND1 ERBB2 ESR1 FGFR2
9 integument MP:0010771 10.31 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
10 adipose tissue MP:0005375 10.3 AKT1 AR CYP19A1 ESR1 FGFR2 MTOR
11 hematopoietic system MP:0005397 10.28 AKT1 AR CCND1 CYP19A1 ESR1 FGFR2
12 embryo MP:0005380 10.27 AKT1 AR ERBB2 ESR1 FGFR2 MTOR
13 digestive/alimentary MP:0005381 10.23 AR CCND1 CYP19A1 ERBB2 ESR1 FGFR2
14 muscle MP:0005369 10.21 AKT1 AR CYP19A1 ERBB2 ESR1 FGFR2
15 neoplasm MP:0002006 10.14 AKT1 AR CCND1 ERBB2 ESR1 FGFR2
16 liver/biliary system MP:0005370 10.13 AKT1 AR CYP19A1 ESR1 FGFR2 NCOA3
17 normal MP:0002873 10.1 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
18 nervous system MP:0003631 10.07 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
19 reproductive system MP:0005389 9.93 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
20 renal/urinary system MP:0005367 9.86 AR CYP19A1 ESR1 FGFR2 MTOR NCOA3
21 respiratory system MP:0005388 9.56 AKT1 CCND1 ERBB2 ESR1 FGFR2 HSPB8
22 skeleton MP:0005390 9.4 AKT1 AR CCND1 CYP19A1 ERBB2 ESR1
Sources

Drugs & Therapeutics for Estrogen-Receptor Positive Breast Cancer

About this section

Drugs for Estrogen-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 223)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129453-61-8 17756771 104741
2
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 107868-30-4 60198
3
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120511-73-1 2187
4
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
5
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
6
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 46835353 5284616 6436030
7
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 70789204 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
9 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
22 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
24 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Antifungal Agents Phase 4,Phase 3,Phase 2
27
Bevacizumab Approved, Investigational Phase 3,Phase 2,Not Applicable 216974-75-3
28
Fluorouracil Approved Phase 3 51-21-8 3385
29
Epirubicin Approved Phase 3 56420-45-2 41867
30
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 57-83-0 5994
31
Docetaxel Approved, Investigational Phase 3,Not Applicable 114977-28-5 148124
32
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
33
Sodium Citrate Approved, Investigational Phase 3,Phase 2,Not Applicable 68-04-2
34
Metformin Approved Phase 3,Phase 2 657-24-9 14219 4091
35
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
36
Norepinephrine Approved Phase 3 51-41-2 439260
37
Goserelin Approved Phase 3,Phase 2 65807-02-5 5311128 47725
38
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
39
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
40
Palbociclib Approved, Investigational Phase 3,Phase 2,Phase 1 571190-30-2 5005498 11431660 5330286
41
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
42
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
43
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
44
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
45
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
46
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
47
Testosterone undecanoate Approved, Investigational Phase 3 5949-44-0
48
Methyltestosterone Approved Phase 3 58-18-4 6010
49
Testosterone enanthate Approved Phase 3 315-37-7 9416
50
Testosterone Approved, Experimental, Investigational Phase 3 58-22-0, 481-30-1 10204 6013

Interventional clinical trials:

(show top 50) (show all 159)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Completed NCT01231659 Phase 4 Everolimus + Letrozole
2 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
3 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
4 Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00893061 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
5 Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
6 Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery Completed NCT00963729 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil;letrozole
7 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Completed NCT01598298 Phase 3 duloxetine hydrochloride
8 S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Completed NCT01385137 Phase 3
9 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
10 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
11 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
12 Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Recruiting NCT02947685 Phase 3 palbociclib;trastuzumab;pertuzumab;letrozole;Anastrozole;Exemestane;Fulvestrant
13 Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial Recruiting NCT03011684 Phase 3 Tamoxifen;Letrozole
14 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Recruiting NCT01674140 Phase 3 anastrozole;everolimus;exemestane;goserelin acetate;letrozole;leuprolide acetate;tamoxifen citrate
15 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Active, not recruiting NCT00265759 Phase 3 anastrozole;exemestane;letrozole
16 Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
17 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066690 Phase 3 Exemestane;Tamoxifen;Triptorelin
18 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066703 Phase 3 exemestane;tamoxifen;triptorelin
19 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
20 Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment Active, not recruiting NCT01573442 Phase 3 testosterone
21 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
22 Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer Active, not recruiting NCT01104571 Phase 3 lapatinib ditosylate
23 A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Active, not recruiting NCT01101438 Phase 3 metformin hydrochloride
24 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Active, not recruiting NCT00433589 Phase 3 anthracycline-based;docetaxel and capecitabine
25 Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery Active, not recruiting NCT00541086 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
26 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
27 A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP） Enrolling by invitation NCT03137368 Phase 3 Exemestane Tablets;Tamoxifen
28 S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Suspended NCT02137837 Phase 3 Fulvestrant;Anastrozole;Everolimus;Placebo - Anastrozole;Placebo - Everolimus
29 Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer Terminated NCT00684216 Phase 2, Phase 3 capecitabine;hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
30 Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients Terminated NCT01809171 Phase 2, Phase 3 Vitamin D3;Placebo
31 Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Unknown status NCT01142401 Phase 2 Bortezomib;Fulvestrant
32 Metformin and Simvastatin in Addition to Fulvestrant Unknown status NCT03192293 Phase 2 Metformin/Simvastatin/Fulvestrant
33 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Unknown status NCT01124695 Phase 2 tamoxifen citrate
34 Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer Unknown status NCT00871858 Phase 2 anastrozole;fulvestrant
35 Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer Unknown status NCT00687648 Phase 2 anastrozole;cyclophosphamide;exemestane;letrozole;methotrexate;prednisolone
36 Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00931450 Phase 1, Phase 2 exemestane;sunitinib malate
37 Fulvestrant (FASLODEXâ„¢) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer Completed NCT00093002 Phase 2 Fulvestrant
38 A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) Completed NCT01234857 Phase 2 ridaforolimus + dalotuzumab;exemestane;ridaforolimus;dalotuzumab
39 Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer Completed NCT00767520 Phase 2 Exemestane + Dasatinib;Exemestane + Placebo
40 Ruxolitinib in Estrogen Receptor Positive Breast Cancer Completed NCT01594216 Phase 2 Ruxolitinib;Exemestane
41 TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer Completed NCT02988986 Phase 2 TAK-228;Tamoxifen
42 A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) Completed NCT01605396 Phase 2 Ridaforolimus;Dalotuzumab;Exemestane
43 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
44 Red Clover and Lifestyle Changes to Contrast Menopausal Symptoms in Premenopausal Breast Cancer Patients Given Tamoxifen Completed NCT03844685 Phase 2 Promensil;Placebo Oral Tablet
45 Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women Completed NCT00107016 Phase 2 RAD001, Letrozole 2.5mg;Letrozole 2.5mg
46 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ Completed NCT01439711 Phase 2 letrozole
47 AKT Inhibitor in Oestrogen Positive Breast Cancer Completed NCT02077569 Phase 2 AZD5363
48 Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer Completed NCT01589367 Phase 2 Metformin;Placebo
49 Estradiol Levels in Patients Treated With Estring Completed NCT01923298 Phase 2 Estradiol
50 AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL) Completed NCT01791985 Phase 1, Phase 2 AZD4547 / anastrozole or letrozole

Search NIH Clinical Center for Estrogen-Receptor Positive Breast Cancer

Sources

Genetic Tests for Estrogen-Receptor Positive Breast Cancer

About this section
Sources

Anatomical Context for Estrogen-Receptor Positive Breast Cancer

About this section

MalaCards organs/tissues related to Estrogen-Receptor Positive Breast Cancer:

42
Breast, Bone, Lung, Lymph Node, Testes, Ovary, Prostate
Sources

Publications for Estrogen-Receptor Positive Breast Cancer

About this section

Articles related to Estrogen-Receptor Positive Breast Cancer:

(show top 50) (show all 436)
# Title Authors Year
1
ESR1 alterations and metastasis in estrogen receptor positive breast cancer. ( 31106278 )
2019
2
Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy. ( 31100952 )
2019
3
Bisphenol AF promotes estrogen receptor-positive breast cancer cell proliferation through amphiregulin-mediated crosstalk with receptor tyrosine kinase signaling. ( 31059536 )
2019
4
Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer. ( 31013327 )
2019
5
MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells. ( 30971760 )
2019
6
Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools. ( 30943126 )
2019
7
Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling. ( 30941654 )
2019
8
Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast Cancer. ( 30824486 )
2019
9
Integrative molecular profiling identifies a novel cluster of ER-positive breast cancer in very young women. ( 30811755 )
2019
10
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. ( 30795773 )
2019
11
MicroRNA and LncRNA Expression Profiles in Human Estrogen Receptor Positive Breast Cancer. ( 30775882 )
2019
12
Interaction between dietary acrylamide intake and genetic variants for estrogen receptor-positive breast cancer risk. ( 29445914 )
2019
13
21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer. ( 30093354 )
2019
14
EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer. ( 30097312 )
2019
15
Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer. ( 30343527 )
2019
16
Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. ( 30368741 )
2019
17
Overall and Estrogen Receptor-Positive Breast Cancer Incidences Are Decreased Following Bariatric Surgery. ( 30536017 )
2019
18
Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial. ( 28798032 )
2018
19
Targeting Cell Necroptosis and Apoptosis Induced by Shikonin via Receptor Interacting Protein Kinases in Estrogen Receptor Positive Breast Cancer Cell Line, MCF-7. ( 28933271 )
2018
20
miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer. ( 28939591 )
2018
21
18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer. ( 28956736 )
2018
22
Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer. ( 28960862 )
2018
23
Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer. ( 29127189 )
2018
24
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer. ( 29128895 )
2018
25
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. ( 29202611 )
2018
26
miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer. ( 29247596 )
2018
27
SRC Increases MYC mRNA Expression in Estrogen Receptor-Positive Breast Cancer via mRNA Stabilization and Inhibition of p53 Function. ( 29263157 )
2018
28
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. ( 29325860 )
2018
29
Omega-3 Polyunsaturated Fatty Acids Time-Dependently Reduce Cell Viability and Oncogenic MicroRNA-21 Expression in Estrogen Receptor-Positive Breast Cancer Cells (MCF-7). ( 29342901 )
2018
30
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. ( 29352052 )
2018
31
Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer. ( 29363090 )
2018
32
Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel. ( 29373839 )
2018
33
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. ( 29436393 )
2018
34
A new class of agents for estrogen-receptor-positive breast cancer. ( 29439601 )
2018
35
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. ( 29450494 )
2018
36
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer. ( 29483206 )
2018
37
18F-Fluoroestradiol PET/CT Correctly Diagnosed 18F-FDG-Avid Inflammatory Lymph Nodes in a Patient With Estrogen Receptor-Positive Breast Cancer. ( 29485433 )
2018
38
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. ( 29562737 )
2018
39
Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer. ( 29626519 )
2018
40
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. ( 29676944 )
2018
41
Alcohol, smoking, and risk of Her2-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer. ( 29708591 )
2018
42
Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. ( 29719270 )
2018
43
A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. ( 29733541 )
2018
44
Wnt5a-induced cell migration is associated with the aggressiveness of estrogen receptor-positive breast cancer. ( 29765514 )
2018
45
Effect of pyruvate kinase M2-regulating aerobic glycolysis on chemotherapy resistance of estrogen receptor-positive breast cancer. ( 29782350 )
2018
46
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer. ( 29867779 )
2018
47
Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients. ( 29895278 )
2018
48
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. ( 29905023 )
2018
49
Expression signature of ten genes predicts the survival of patients with estrogen receptor positive-breast cancer that were treated with tamoxifen. ( 29928444 )
2018
50
MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway. ( 30016800 )
2018
Sources

Variations for Estrogen-Receptor Positive Breast Cancer

About this section
Sources

Expression for Estrogen-Receptor Positive Breast Cancer

About this section
Search GEO for disease gene expression data for Estrogen-Receptor Positive Breast Cancer.
Sources

Pathways for Estrogen-Receptor Positive Breast Cancer

About this section

Pathways related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 67
Show member pathways
 14.23 AKT1 AR CCND1 ERBB2 ESR1 FGFR2
2
Akt Signaling 65
Show member pathways
 13.48 AKT1 AR CCND1 ERBB2 FGFR2 MTOR
3
Cytokine Signaling in Immune system 67
Show member pathways
 13.41 AKT1 CCND1 ERBB2 FGFR2 PIK3CA STAT5B
4
PI3K-Akt signaling pathway 38
Show member pathways
 13.04 AKT1 CCND1 ERBB2 FGFR2 MTOR PIK3CA
5
Human cytomegalovirus infection 38
Show member pathways
 13.02 AKT1 CCND1 MTOR PIK3CA STAT5B TP53
6
CCR5 Pathway in Macrophages 65
Show member pathways
 12.93 AKT1 AR CCND1 PIK3CA STAT5B
7
NFAT and Cardiac Hypertrophy 65
Show member pathways
 12.91 AKT1 ERBB2 FGFR2 MTOR PIK3CA
8
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 66
Show member pathways
 12.83 AKT1 CCND1 MTOR PIK3CA STAT5B
9
Endometrial cancer 38
Show member pathways
 12.83 AKT1 AR CCND1 ERBB2 FGFR2 MTOR
10
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.79 AKT1 ERBB2 FGFR2 MTOR PIK3CA TP53
11
Development HGF signaling pathway 23
Show member pathways
 12.77 AKT1 ERBB2 ESR1 MTOR PIK3CA TP53
12
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.74 AKT1 CCND1 MTOR PIK3CA STAT5B
13
Immune response IL-23 signaling pathway 23
Show member pathways
 12.66 AKT1 ERBB2 PIK3CA STAT5B TP53
14
MicroRNAs in cancer 38
12.6 CCND1 ERBB2 MTOR PIK3CA TP53
15
ErbB signaling pathway 1 38
Show member pathways
 12.59 AKT1 CCND1 ERBB2 MTOR PIK3CA STAT5B
16
Development EGFR signaling pathway 23
Show member pathways
 12.58 AKT1 CCND1 ERBB2 MTOR PIK3CA TP53
17
mTOR signaling pathway (KEGG) 38
Show member pathways
 12.55 AKT1 ERBB2 FGFR2 MTOR PIK3CA TP53
18
Glioma 38
Show member pathways
 12.55 AKT1 CCND1 ERBB2 ESR1 FGFR2 MTOR
19
Gastric cancer 38
Show member pathways
 12.52 AKT1 CCND1 ERBB2 ESR1 FGFR2 MTOR
20
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.51 AKT1 CCND1 MTOR PIK3CA TP53
21
Prolactin Signaling Pathway 1 38
Show member pathways
 12.51 AKT1 CCND1 ERBB2 ESR1 MTOR PIK3CA
22
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.48 AKT1 CCND1 MTOR PIK3CA STAT5B
23
mTOR signalling 67
Show member pathways
 12.47 AKT1 FGFR2 MTOR PIK3CA
24
Apoptosis Pathway 73
Show member pathways
 12.47 AKT1 ERBB2 FGFR2 MTOR PIK3CA TP53
25
Human T-cell leukemia virus 1 infection 38
12.43 AKT1 CCND1 PIK3CA STAT5B TP53
26
Development IGF-1 receptor signaling 23
Show member pathways
 12.42 AKT1 CCND1 MTOR PIK3CA STAT5B TP53
27
Oocyte meiosis 38
Show member pathways
 12.41 AKT1 AR PGR PIK3CA
28
Viral carcinogenesis 38
12.36 CCND1 PIK3CA STAT5B TP53
29
Development Ligand-independent activation of ESR1 and ESR2 23
Show member pathways
 12.34 AKT1 CCND1 ERBB2 ESR1 NCOA3 PIK3CA
30
G-protein signaling Ras family GTPases in kinase cascades (scheme) 23
Show member pathways
 12.31 AKT1 MTOR STAT5B TP53
31
Proteoglycans in cancer 38
12.3 AKT1 CCND1 ERBB2 ESR1 MTOR PIK3CA
32
Cell cycle Role of SCF complex in cell cycle regulation 23
Show member pathways
 12.29 CCND1 ESR1 NCOA3 PGR
33
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 12.24 AKT1 FGFR2 MTOR PIK3CA
34
mTOR Pathway 73
Show member pathways
 12.24 AKT1 MTOR PIK3CA TP53
35
EGF/EGFR Signaling Pathway 1
12.24 AKT1 ERBB2 MTOR NCOA3 STAT5B
36
Cellular senescence (KEGG) 38
12.22 AKT1 CCND1 MTOR PIK3CA TP53
37
Longevity regulating pathway 38
Show member pathways
 12.21 AKT1 MTOR PIK3CA TP53
38
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.21 AKT1 CCND1 ERBB2 FGFR2 MTOR PIK3CA
39
Transcription Androgen Receptor nuclear signaling 23
Show member pathways
 12.17 AKT1 AR CCND1 ERBB2 MTOR PIK3CA
40
MAPK Pathway 73
Show member pathways
 12.11 AKT1 ERBB2 PIK3CA TP53
41
AKT Signaling Pathway 68
12.1 AKT1 CCND1 ERBB2 FGFR2 MTOR PIK3CA
42
Pathways in cancer 38
12.09 AKT1 AR CCND1 ERBB2 ESR1 FGFR2
43
Glioblastoma Multiforme 65
12.05 AKT1 CCND1 MTOR TP53
44
DNA Damage Response (only ATM dependent) 1
12.03 AKT1 CCND1 ERBB2 PIK3CA TP53
45
HIF-1 signaling pathway 38
11.99 AKT1 ERBB2 MTOR PIK3CA
46
AGE-RAGE signaling pathway in diabetic complications 38
11.99 AKT1 CCND1 PIK3CA STAT5B
47
Signaling by ERBB4 67
Show member pathways
 11.98 ERBB2 ESR1 PGR PIK3CA STAT5B
48
Jak-Stat Signaling Pathway (sino) 68
11.97 AKT1 MTOR PIK3CA STAT5B
49
ErbB1 downstream signaling 1
11.96 AKT1 MTOR PIK3CA
50
TGF-beta Signaling Pathways 66
11.96 AKT1 AR ESR1 MTOR
Sources

GO Terms for Estrogen-Receptor Positive Breast Cancer

About this section

Cellular components related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.77 AKT1 AR CCND1 ERBB2 ESR1 HSPB8
2 protein-containing complex GO:0032991 9.63 AKT1 AR ESR1 MTOR NCOA3 TP53
3 nuclear chromatin GO:0000790 9.56 AR ESR1 NCOA3 TP53
4 nucleoplasm GO:0005654 9.4 AKT1 AR CCND1 ESR1 FGFR2 FOXA1
5 cytoplasm GO:0005737 10.18 AKT1 AR CCND1 ERBB2 ESR1 FGFR2
6 nucleus GO:0005634 10.13 AKT1 AR CCND1 ERBB2 ESR1 FGFR2

Biological processes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.98 AKT1 FOXA1 NUS1 TP53
2 cytokine-mediated signaling pathway GO:0019221 9.91 AKT1 CCND1 PIK3CA STAT5B TP53
3 positive regulation of gene expression GO:0010628 9.91 AKT1 AR ERBB2 MTOR NCOA3 TP53
4 protein phosphorylation GO:0006468 9.91 AKT1 CCND1 ERBB2 FGFR2 HSPB8 MTOR
5 positive regulation of protein phosphorylation GO:0001934 9.9 AKT1 CCND1 ERBB2 MTOR
6 transcription initiation from RNA polymerase II promoter GO:0006367 9.88 AR CCND1 ESR1 PGR
7 protein autophosphorylation GO:0046777 9.88 AKT1 ERBB2 FGFR2 MTOR
8 wound healing GO:0042060 9.86 ERBB2 FGFR2 MTOR
9 negative regulation of apoptotic process GO:0043066 9.85 AKT1 STAT5B TP53
10 multicellular organism growth GO:0035264 9.84 AR FGFR2 MTOR
11 cellular response to growth factor stimulus GO:0071363 9.79 AKT1 ERBB2 STAT5B
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.79 AKT1 FGFR2 MTOR
13 steroid hormone mediated signaling pathway GO:0043401 9.77 AR ESR1 PGR
14 response to estradiol GO:0032355 9.76 CCND1 ESR1 FOXA1 STAT5B
15 cellular response to epidermal growth factor stimulus GO:0071364 9.74 AKT1 ERBB2 STAT5B
16 phosphatidylinositol 3-kinase signaling GO:0014065 9.7 AKT1 ERBB2 PIK3CA
17 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.67 AR FOXA1
18 regulation of multicellular organism growth GO:0040014 9.67 FGFR2 PIK3CA STAT5B
19 Leydig cell differentiation GO:0033327 9.66 AR CCND1
20 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.66 ESR1 TP53
21 negative regulation of cell size GO:0045792 9.65 AKT1 MTOR
22 mitotic G1 DNA damage checkpoint GO:0031571 9.65 CCND1 TP53
23 reproductive structure development GO:0048608 9.65 AR FGFR2
24 positive regulation of protein kinase B signaling GO:0051897 9.65 ERBB2 ESR1 FGFR2 MTOR PIK3CA
25 prostate gland epithelium morphogenesis GO:0060740 9.64 AR FOXA1
26 prostate gland growth GO:0060736 9.63 AR CYP19A1
27 regulation of branching involved in prostate gland morphogenesis GO:0060687 9.63 ESR1 FGFR2
28 regulation of glycogen biosynthetic process GO:0005979 9.62 AKT1 MTOR
29 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis GO:0060527 9.61 ESR1 FGFR2
30 mammary gland alveolus development GO:0060749 9.58 AR CCND1 ESR1
31 prostate epithelial cord elongation GO:0060523 9.56 ESR1 FGFR2
32 response to UV-A GO:0070141 9.55 AKT1 CCND1
33 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.54 AR PGR
34 negative regulation of macroautophagy GO:0016242 9.5 AKT1 MTOR PIK3CA
35 anoikis GO:0043276 9.33 AKT1 MTOR PIK3CA
36 positive regulation of transcription by RNA polymerase II GO:0045944 9.28 AKT1 AR ESR1 FGFR2 FOXA1 NCOA3
37 phosphatidylinositol phosphorylation GO:0046854 9.18 PIK3CA
38 positive regulation of transcription by RNA polymerase III GO:0045945 8.96 AR MTOR
39 regulation of transcription, DNA-templated GO:0006355 10.23 AR ESR1 FOXA1 NCOA3 PGR STAT5B
40 negative regulation of transcription by RNA polymerase II GO:0000122 10.12 AR CCND1 ESR1 FGFR2 FOXA1 TP53
41 positive regulation of cell proliferation GO:0008284 10.07 AKT1 AR CCND1 FGFR2 STAT5B

Molecular functions related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.95 AKT1 ERBB2 ESR1 HSPB8 MTOR PGR
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.91 AR ESR1 PGR STAT5B TP53
3 kinase activity GO:0016301 9.91 AKT1 CCND1 ERBB2 FGFR2 MTOR PIK3CA
4 protein kinase binding GO:0019901 9.89 AKT1 CCND1 ESR1 MTOR TP53
5 protein dimerization activity GO:0046983 9.78 AR ERBB2 NCOA3 STAT5B
6 protein kinase activity GO:0004672 9.73 AKT1 CCND1 ERBB2 FGFR2 HSPB8 MTOR
7 transcription factor binding GO:0008134 9.72 AR CCND1 ESR1 FOXA1 TP53
8 ATPase binding GO:0051117 9.71 AR ESR1 PGR
9 steroid hormone receptor activity GO:0003707 9.63 AR ESR1 PGR
10 nuclear receptor activity GO:0004879 9.54 AR ESR1 PGR
11 nitric-oxide synthase regulator activity GO:0030235 9.52 AKT1 ESR1
12 enzyme binding GO:0019899 9.43 AKT1 AR CCND1 ESR1 PGR TP53
13 steroid binding GO:0005496 9.33 AR ESR1 PGR
14 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.32 PIK3CA
15 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 10.1 AR ESR1 FOXA1 NCOA3 PGR STAT5B
16 DNA-binding transcription factor activity GO:0003700 10.02 AR ESR1 FOXA1 PGR STAT5B TP53
Sources

Sources for Estrogen-Receptor Positive Breast Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....